StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc (VRTX) KPIs and segments

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3030% above fair value
$534.20−3.59 (-0.67%)

Close on Nov 17, 2026Market cap $135.40BP/E 31.1Yield –

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Vertex Pharmaceuticals · năm tài chính kết thúc Calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026)

Nhìn nhanh KPI của Vertex Pharmaceuticals: 45 chỉ số vận hành, trong đó có Estimated Cystic Fibrosis patient population in U.S., JOURNAVX và CASGEVY, lấy từ 218 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Products($M)
3,3342,9873,1903,0762,9442,7602,9122,7722,6462,691
TRIKAFTA/KAFTRIO($M)
2,4972,3552,5732,6542,5512,5362,7212,5852,4492,4842,3332,274
ALYFTREK($M)
57442438024715753.90000
Other CF product revenues($M)
137136237176194155191187196207184209
CASGEVY($M)
76.442.954.316.930.414.2820
JOURNAVX($M)
49.62926.719.6121.30000
Other revenues($M)
000020.7100000
Kỳ báo cáo trước đây (báo cáo lần cuối 2025)5
United States($M)
2,0561,7761,9761,8481,6641,8371,7141,6141,5201,5751,554
Europe($M)
978950837911827832848807967735767
Other($M)
300261263206280211225203163
JOURNAVX (suzetrigine, non-opioid NaV1.8 pain signal inhibitor) — Quarterly prescriptions filled (Rx)1
535,000.00350,000.00280,000.00170,000.0090,000.0010,000.00
JOURNAVX — State Medicaid plans with fee-for-service coverage (states)
21.0019.0016.0010.00
CASGEVY (exagamglogene autotemcel, CRISPR/Cas9 gene-edited therapy) — Patient infusions in period (patients)2
30.0010.0016.008.00
CASGEVY — Patients with first cell collection in period (patients)
37.0050.0035.0025.00
CASGEVY — Cumulative patients with cell collections since launch (patients)
165.00115.0090.0050.0040.0020.00
Total consolidated revenues ($M)($M)1
3,3342,9873,1903,0762,9652,7702,9122,7722,6462,6912,5182,484
Foreign currency cash flow hedge gain (loss) reclassified to net product revenues ($M)($M)
-10.2-25.5-37.1-39-21.324.124.5-3.1010.93.40-2.802.80
Net product revenues by geography — United States (U.S.) ($M)($M)1
2,0561,7762,0911,9761,8481,6641,8371,7141,6141,5201,5751,554
Outside the United States (Ex-U.S. total net product revenues, $M)($M)2
1,2781,2111,1291,1001,1171,1071,0751,0581,0311,171943929
Europe — Net product revenues ($M)($M)
978950886837911827832848807967735767
Other international markets (Ex-U.S. & Ex-Europe) — Net product revenues ($M)($M)
300261244263206280243211225203208163
Total contract liabilities (deferred product & collaborative revenue, $M)($M)1
157219172182147228207220128276170157
Contract liabilities — Annual reimbursement cap contracts for CF medicines in ex-U.S. government markets ($M)($M)
157219172182147228207220128276170157
Total accrued expenses ($M)($M)
3,1792,9842,9713,6143,2712,9522,7893,2202,9402,7962,6552,907
Level 3 contingent consideration liabilities — Total fair value ($M)($M)5
79.679.27978.18079.176.978.177.877.377.4128
Contingent consideration liabilities — Noncurrent ($M)($M)
79.679.27978.18079.176.978.177.877.377.4113
Contingent consideration liabilities — Current (historical, $M)($M)
015
Contingent consideration — Remaining potential development & regulatory milestones (historical, $M)($M)
678678
Contingent consideration valuation — Discount rate range minimum (%)(%)
460.0%440.0%410.0%420.0%440.0%450.0%490.0%430.0%510.0%510.0%470.0%550.0%
Contingent consideration valuation — Discount rate range maximum (%)(%)
470.0%460.0%450.0%450.0%460.0%460.0%510.0%440.0%560.0%530.0%490.0%650.0%
Total Research and Development (R&D) expenses ($M)($M)2
994962974978978980999876967789825810
Research expenses (discovery & early preclinical) — Total ($M)($M)4
207205203210209206207194207196194174
Research — Salary and employee benefits ($M)($M)
51.355.248.149.653.153.147.548.361.95346.646.3
Research — Stock-based compensation expense ($M)($M)
21.221.2222822.522.324.229.428.629.933.220.5
Research — Outsourced services and other direct costs ($M)($M)
71.266.669.972.27173.175.964.16764.46161.8
Research — Infrastructure and facilities costs ($M)($M)
63.66262.560.262.757.659.75249.848.853.445.3
Development expenses (clinical trials, regulatory & CMC) — Total ($M)($M)4
787757771768769774791682759593630636
Development — Outsourced clinical trials, CROs, manufacturing & other direct costs ($M)($M)
368326377365373380416319267236282333
Development — Salary and employee benefits ($M)($M)
194213179182187196177173167170152152
Development — Stock-based compensation expense ($M)($M)
83.280.577.78877.177.874.181.668.589.589.860.6
Development — Infrastructure and facilities costs ($M)($M)
14213713813313212012410810597.310790.6
Acquired in-process research and development (AIPR&D) expenses ($M)($M)1
21.40.5056.554.52.2019.887.5154,44976.817.851.7
Intangible asset (IPR&D) impairment charges ($M)($M)
000003790000
Cost of sales — Total ($M)($M)3
489393466415408363423393372343368319
Cost of sales — Product manufacturing, logistics & write-downs (ex-royalties, $M)($M)
218160191140141131152132124109
Cost of sales — Royalty expense (CFF & third-party royalties, $M)($M)
271233275275267232271261248234
Cost of sales as % of net product revenues (%)(%)
14.7%13.2%13.5%13.8%13.2%14.2%13.0%13.0%13.0%
Selling, general and administrative (SG&A) expenses — Total ($M)($M)3
582494487445425396378372372343369264
SG&A — Selling and marketing expenses ($M)($M)
388314319278265241234217196192
SG&A — General and administrative expenses ($M)($M)
194180168167160155144155176151
Segment other items (other operating & non-operating segment items, $M)($M)
-23.90.20-2.3011.2-12.319.816.524.733.541.5
CRISPR Therapeutics Collaboration (CASGEVY JDCA, 60% VRTX / 40% CRISPR) — Net R&D expense ($M)($M)4
14.416.116.814.315.116-3.4011.711.611.713.612.5
CRISPR Collaboration — Cost of sales / collaboration profit-sharing ($M)($M)
21.823.137.243.330.136.22615.815.915.8
CRISPR Collaboration — Pre-commercialization SG&A expense (historical, $M)($M)
10.97
CRISPR Collaboration — Vertex share of CASGEVY net profits / losses (%)(%)
4,000.0%4,000.0%4,000.0%4,000.0%4,000.0%4,000.0%4,000.0%4,000.0%4,000.0%4,000.0%4,000.0%
CRISPR Collaboration — Vertex share of program development costs (%)(%)
4,000.0%4,000.0%4,000.0%4,000.0%4,000.0%4,000.0%4,000.0%4,000.0%4,000.0%4,000.0%4,000.0%
Non-GAAP net income ($M)($M)6
1,2071,1471,2871,2361,1691,0541,0361,143-3,3111,2421,0971,064
Non-GAAP diluted earnings per share ($/sh)($)
4.734.475.034.804.524.063.984.38-12.834.764.204.08
Non-GAAP operating income ($M)($M)
1,4231,3101,3701,3851,3251,1831,1981,307-3,1461,3361,1511,173
Non-GAAP combined R&D, AIPR&D and SG&A expenses ($M)($M)2
1,4301,2921,3621,2851,2401,2321,2971,0795,4271,019984942
Non-GAAP research and development (R&D) expenses ($M)($M)
889859873861878879900764697670699726
Non-GAAP selling, general and administrative (SG&A) expenses ($M)($M)
520432432369359333310300280272286216
Non-GAAP cost of sales ($M)($M)
480385458407400355416386365336364317
Total pre-tax Non-GAAP adjustments (SBC, intangible amortization, contingent consideration & acquisition costs, $M)($M)
139174157201169568180202381224163141
Non-GAAP provision for income taxes ($M)($M)2
324280201264282244280283301261214257
Non-GAAP effective tax rate (%)(%)
21.1%19.6%13.5%17.6%19.4%18.8%21.3%19.8%-10.0%17.4%16.3%19.4%
GAAP effective tax rate (%)(%)
21.0%17.7%10.5%16.6%19.5%11.5%19.7%14.6%-6.0%14.0%15.6%12.2%
Total stock-based compensation (SBC) expense recognized in income statement ($M)($M)7
170166158195167166168185154192209131
SBC expense — Research and development ($M)($M)
10410299.711699.610098.311197.111912381.1
SBC expense — Selling, general and administrative ($M)($M)
6261.554.776.165.263.467.571.755.370.783.548.1
SBC expense — Cost of sales ($M)($M)
3.803.203.202.802.502.6021.901.801.802.101.70
SBC capitalized into inventory ($M)($M)
3.703.503.204.403.902.903.103.602.801.100.500.80
Total gross stock-based compensation cost incurred (expensed + capitalized, $M)($M)
170166158195167166168185154192209131
Income tax benefit (provision) recognized for stock-based compensation ($M)($M)
35.335.3-30.647.536.575.227.364.680.77958.537.1
Stock-based compensation expense, net of tax ($M)($M)
13513118814713190.914112073.511315093.8
SBC expense by award type — Restricted stock units (RSUs) & performance stock units (PSUs) ($M)($M)2
166167155191163163166185151187205129
SBC expense by award type — Stock options ($M)($M)
2.20001.20001.80000.20
SBC expense by award type — Employee stock purchase plan (ESPP) ($M)($M)
5.803.405.808.507.105.604.503.404.505.8042.40
Total inventories, net ($M)($M)3
1,7651,7671,6871,6271,4991,3601,2051,080915813739689
Inventories — Raw materials ($M)($M)
23326726027922125125214111295.778.777.5
Inventories — Work in process ($M)($M)
1,2541,2431,1971,0961,064901769750658602525498
Inventories — Finished goods ($M)($M)
278256230252214208185189145116135113
Property and equipment, net ($M)($M)
1,6651,6081,5201,4251,3351,2961,2281,1181,2011,1731,1591,124
Intangible assets, net ($M)($M)4
413419424430436441826832838835840604
Indefinite-lived in-process research and development (IPR&D) intangible assets ($M)($M)
225225225225225225604604
Finite-lived intangible assets — Commercialized / marketing-related, net ($M)($M)2
186191196201206211216236
Finite-lived marketing-related intangible assets — Gross carrying amount ($M)($M)
238238238238238238238238
Finite-lived marketing-related intangible assets — Accumulated amortization ($M)($M)
52.247.142.1373226.921.91.70
Finite-lived intangible assets — Employment contracts, net ($M)($M)
2.4033.704.204.905.506.200
Goodwill carrying value ($M)($M)
1,0881,0881,0881,0881,0881,0881,1001,0881,0881,0881,1001,088
Operating lease right-of-use (ROU) assets ($M)($M)1
1,6631,6851,5631,5921,3141,3391,3571,396570313294311
Operating lease liabilities — Total ($M)1
Operating lease liabilities — Noncurrent ($M)($M)
1,9781,9871,8471,8351,5271,5381,5441,589587360349354
Share repurchases — Cash paid for repurchases of common stock ($M)($M)4
4703371281,071392426418308320131150117
Share repurchases — Aggregate repurchase value under repurchase programs ($M)($M)
45834593.31,093397417436308316140144123
Share repurchases — Shares repurchased under repurchase programs (M shares)(M)
1.100.700.302.700.900.9010.600.800.300.400.40
Item 2(c) / Item 5 Share Repurchases — Total shares purchased in quarter (thousands)3
1,033.70741.10256.802,728.20868.70932.50961.10640.00736.00335.80398.00352.60
Item 2(c) / Item 5 — Shares purchased under publicly announced programs in quarter (thousands)
1,033.70741.10256.802,728.20868.70932.50961.10640.00736.00335.80398.00352.60
Item 2(c) / Item 5 — Quarterly volume-weighted average price paid per share ($/sh)($)
440465409397454447445481429418361349
Item 2(c) / Item 5 — Remaining share repurchase authorization at quarter-end ($M)($M)
2,5823,0373,3823,4874,5709641,3811,8092,1162,4322,5722,716
Employee tax withholding — Cash paid for shares withheld on equity vesting ($M)($M)1
4.302292.50915.902717.3083.780.52343.2053.2
Employee tax withholding — Shares withheld on equity vesting (M shares)(M)
00.50-0.100.2000.6000.200.100.6000.10
Income before provision for income taxes — Total ($M)($M)
1,3921,2531,3311,2991,2837301,1371,224-3,3911,2791,1481,179
Provision for (benefit from) income taxes — Total ($M)($M)
29222214021625084.1224179202180179144
Unrecognized tax benefits (UTB) — Gross ending balance ($M)1
UTB — Portion that would impact effective tax rate if recognized ($M)($M)
439420437422412357341345309302289245
Alpine Immune Sciences, Inc. (CIK 0001626199, acquired May 2024 for povetacicept, $4.9B) — Pre-acquisition R&D expense ($M)($M)11
22.522.919.2
Alpine Immune Sciences — Collaboration revenue ($M)($M)
7.0330.910.0
Alpine Immune Sciences — General and administrative expense ($M)($M)
7.276.375.44
Alpine Immune Sciences — Total operating expenses ($M)($M)
29.729.324.6
Alpine Immune Sciences — Operating income (loss) ($M)($M)
-22.71.54-14.6
Alpine Immune Sciences — Net income (loss) ($M)($M)
-17.95.97-11.7
Alpine Immune Sciences — Stock-based compensation expense ($M)($M)
3.992.812.65
Alpine Immune Sciences — Cash and cash equivalents ($M)($M)
33.043.919.0
Alpine Immune Sciences — Marketable securities ($M)($M)
273283174
Alpine Immune Sciences — Total assets ($M)($M)
374380241
Alpine Immune Sciences — Total liabilities ($M)($M)
40.951.978.9
Alpine Immune Sciences — Stockholders' equity ($M)($M)
333328162
Crinetics Pharmaceuticals, Inc. (CIK 0001699813, July 2026 acquisition agreement for PALSONIFY, ~$8.8B) — R&D expense ($M)($M)9
99.910085.190.580.376.266.661.958.353.345.643.8
Crinetics Pharmaceuticals — Total revenues ($M)($M)
25.110.76.170.141.030.36000.400.64-0.010.35
Crinetics Pharmaceuticals — Operating loss ($M)($M)
-132-140-134-143-129-111-94.7-87.8-82.8-73.5-62.7-59.0
Crinetics Pharmaceuticals — Net loss ($M)($M)
-121-128-123-130-116-96.8-80.6-76.8-74.1-66.9-60.1-57.5
Crinetics Pharmaceuticals — Stock-based compensation expense ($M)($M)
24.929.721.722.726.120.518.918.218.913.511.611.1
Crinetics Pharmaceuticals — Cash and cash equivalents ($M)($M)
55.511410211153.794.626531730239654.9143
Crinetics Pharmaceuticals — Investment securities ($M)($M)
1,1501,1779269811,1431,1801,090545561505504412
Crinetics Pharmaceuticals — Total assets ($M)($M)
1,3221,4011,1261,1961,2901,3611,435937936978635642
Crinetics Pharmaceuticals — Total liabilities ($M)($M)
13012113412411810711010410510396.393.8
Crinetics Pharmaceuticals — Stockholders' equity ($M)($M)
1,1921,2819921,0721,1721,2541,325833831875539548
U.S. Producer Price Index (PPI) — Pharmaceutical Preparation Manufacturing (PCU325412325412, index)7
926.20926.00919.30918.70914.80916.50918.50918.10914.00909.00896.40896.00
U.S. PPI — Biological Product (ex-Diagnostic) Manufacturing (PCU325414325414, index)
266.30266.30264.10264.10261.90261.90258.30258.00255.20256.80254.50254.50
U.S. PPI — Pharmaceutical & Medicine Manufacturing (PCU3254132541, index)
245.70245.80244.30244.00242.90242.80242.40242.30241.20240.30237.20236.90
U.S. Consumer Price Index (CPI-U) — Medical Care Commodities, Seasonally Adjusted (CUSR0000SAM1, index)
409.00414.00416.50417.60413.00412.40413.70416.80408.90410.40407.20
U.S. CPI-U — Medical Care Commodities, Not Seasonally Adjusted (CUUR0000SAM1, index)
409.00414.00416.50417.60413.00412.40413.70416.80408.90410.40407.20
U.S. CPI-U — Medical Care, Seasonally Adjusted (CPIMEDSL, index)
592.30591.60584.90580.50574.10570.10566.30565.00559.30554.40548.40
U.S. Real Personal Consumption Expenditures — Health Care Services (DHLCRC1Q027SBEA, $B SAAR)
3,790.303,699.903,667.003,614.903,529.803,464.703,417.803,358.203,288.203,244.403,159.403,079.00
U.S. Employment — Health Care & Social Assistance All Employees (CES6562000001, thousands)
23,887.2023,756.7023,587.5023,438.2023,277.5023,076.0022,901.4022,673.6022,493.7022,276.6022,018.7021,761.70
Income Statement — Total revenues ($M)($M)13
3,3342,9873,1903,0762,9652,7702,9122,7722,6462,6912,5182,484
Cost of sales ($M)($M)
489393466415408363423393372343368319
Research and development expenses ($M)($M)
994962974978978980999876967789825810
Selling, general and administrative expenses ($M)($M)
582494487445425396378372372343369264
Total costs and expenses ($M)($M)
2,0871,8491,9841,8901,8142,1401,8861,6566,1601,5511,5291,445
Operating income (loss) ($M)($M)
1,2471,1381,2061,1861,1516301,0261,116-3,5151,1409891,038
Other non-operating income (expense), net ($M)($M)
24.306.50-9.8013.2-17.6-14.9-16.9-23.1-31.2-9.80-15.9
Income (loss) before provision for income taxes ($M)($M)
1,3921,2531,3311,2991,2837301,1371,224-3,3911,2791,1481,179
Provision for (benefit from) income taxes ($M)($M)
29222214021625084.1224179202180179144
Net income (loss) ($M)($M)
1,1001,0311,1911,0831,0336469131,045-3,5941,1009691,035
Earnings per share — Basic ($/sh)($)
4.344.064.244.022.524.05-13.924.264.01
Earnings per share — Diluted ($/sh)($)
4.314.024.203.992.494.01-13.924.213.97
Weighted-average basic shares (M)(M)
254254256257257258258258258
Weighted-average diluted shares (M)(M)
255256258259260261258261261
Balance Sheet — Total assets ($M)($M)24
27,42326,48425,64324,86224,03722,88122,53322,24020,13223,91722,73021,726
Cash and cash equivalents ($M)($M)
6,1445,4935,0854,9404,9724,6754,5705,2394,5809,15810,36911,110
Marketable securities ($M)($M)
1,7091,7541,5231,3471,4111,5271,5461,2851,2151,013849818
Accounts receivable, net ($M)($M)
2,1341,9962,0531,9461,8941,8051,6091,7511,6561,7931,5631,539
Inventories ($M)($M)
1,7651,7671,6871,6271,4991,3601,2051,080915813739689
Prepaid expenses and other current assets ($M)($M)
792721853709652643666449575511624540
Total current assets ($M)($M)
12,54411,73011,20110,57010,42810,0099,5969,8048,94213,28914,14414,696
Property and equipment, net ($M)($M)
1,6651,6081,5201,4251,3351,2961,2281,1181,2011,1731,1591,124
Goodwill ($M)($M)
1,0881,0881,0881,0881,0881,0881,0881,0881,0881,0881,0881,088
Intangible assets, net ($M)($M)
413419424430436441826832838835840604
Operating lease right-of-use assets ($M)($M)
1,6631,6851,5631,5921,3141,3391,3571,396570313294311
Deferred tax assets ($M)($M)
3,0112,9482,8982,9372,7122,5442,3312,3092,1861,9631,8121,729
Other noncurrent assets ($M)($M)
1,2511,2561,2371,0981,0791,007999990916876895475
Accounts payable ($M)($M)
430489462420442445413396328351365376
Accrued expenses ($M)($M)
3,1792,9842,9713,6143,2712,9522,7893,2202,9402,7962,6552,907
Other current liabilities ($M)($M)
329407428442425386363358279649527316
Total current liabilities ($M)($M)
3,9383,8813,8614,4754,1383,7833,5653,9733,5473,7963,5473,599
Noncurrent operating lease liabilities ($M)($M)
1,9781,9871,8471,8351,5271,5381,5441,589587360349354
Other long-term liabilities ($M)($M)
1,2601,2551,2701,2331,1969521,015933877854878869
Total liabilities ($M)($M)
7,1757,1236,9777,5446,8616,3846,1246,6095,3575,3715,1505,213
Additional paid-in capital ($M)($M)
4,5064,7435,1195,0125,9886,1736,6726,9067,1017,2857,4507,340
Retained earnings (accumulated deficit) ($M)($M)
15,69114,59113,56012,36911,28610,2539,6078,6947,64811,24210,1429,174
Accumulated other comprehensive income (loss) ($M)($M)
48.524.8-15.9-64.5-10168.112828.822.517.3-14.3-3
Total stockholders' equity ($M)($M)
20,24819,36218,66617,31917,17516,49616,41015,63114,77518,54717,58016,513
Common shares outstanding at period-end (M)(M)
253254254254256257257258258258258258
Cash Flow — Operating cash flow ($M)($M)10
1,1251,4284981,2411,0738195851,370-3,7541,3072351,268
Depreciation and amortization ($M)($M)
56.555.955.75451.748.446.553.25453.55942.1
Stock-based compensation ($M)($M)
170166158195167166168185154192209131
Change in accounts receivable ($M)($M)
-14039.8-99.4-59.9-18.4-17069-51.8135-25215.4-6.10
Change in inventories ($M)($M)
-27.7-97.7-77.4-131-149-167-148-183-107-80.1-70-97.5
Change in accounts payable and accrued expenses ($M)($M)
-66.735.638.3-35.37.6026.28.4066.1-25.10.10-31.89.20
Capital expenditures ($M)($M)
11213314910214640.792.667.76968.458.140.6
Net cash used in investing activities ($M)($M)
-45.8-432-288-117-485-55.8-822-348-464-2,136-887-118
Repurchases of common stock ($M)($M)
4703371281,071392426418308320131150117
Net cash used in financing activities ($M)($M)
-427-539-77.2-1,155-349-680-391-388-359-358-120-165
Cash paid for income taxes ($M)($M)
41982.338948051318427227949734.8758300

13 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Fiscal calendar: Vertex Pharmaceuticals Incorporated operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q1 2026 ended March 31, 2026; Q2 2026 ended June 30, 2026). Vertex operates as a single global human therapeutics operating segment (pharmaceuticals), disaggregating commercial performance across its Cystic Fibrosis (CF) portfolio (TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI, KALYDECO), Diversified Launch portfolio (CASGEVY gene-edited therapy and JOURNAVX non-opioid pain inhibitor), and Geographic markets (U.S. vs. Ex-U.S. [Europe & Other International]).
  • Core operational & commercial KPIs (Groups 1–5) cover: (1) Commercial Launch, Patient Access & Wholesaler Concentration (Core CF addressable population of 97,000 patients in FY25; JOURNAVX prescriptions filled reaching 535,000 in Q2 2026 after 350,000 in Q1 2026 and 550,000 in FY25, with 21 state Medicaid plans at FY25; CASGEVY patient infusions of 64 in FY25 [30 in Q4 2025] and 147 first cell collections in FY25; Customer Concentration across McKesson 32% of gross revenue, Accredo 26%, and Lloyds Pharmacy 15% in FY25); (2) Net Product & Collaborative Revenues by Brand & Geography ($3,381.9M in Q2 2026 / $12,003.0M in FY25 across TRIKAFTA/KAFTRIO $2,505.5M, ALYFTREK $430.5M, CASGEVY $67.7M, JOURNAVX $66.3M, Other CF $277.6M in Q2 2026; U.S. $2,115.6M vs. Ex-U.S. $1,232.0M in Q2 2026); (3) Gross-to-Net (GTN) Rebate Accruals Rollforward ($4,043.6M current-year provision and $1,984.9M ending balance at FY25), Ex-U.S. CF Annual Reimbursement Cap Contract Liabilities ($265.2M at Q2 2026), Accrued Expenses breakdown, and Level 3 Contingent Consideration; (4) Granular R&D Disaggregation (Research $235.1M vs. Development $795.4M in Q2 2026 broken down into Salary & Benefits, SBC, Outsourced CRO/Clinical Services, and Infrastructure), Segment Expenses (Product COGS vs. Royalty COGS, Selling vs. G&A), and CRISPR Therapeutics CASGEVY JDCA (60%/40% profit/cost split); and (5) Form 8-K GAAP to Non-GAAP Reconciliations ($1,301.2M Non-GAAP Net Income and $5.03 Non-GAAP Diluted EPS in Q2 2026).
  • Extended operational, subsidiary & ESG KPIs (Groups 6–11) cover: (6) Stock-Based Compensation by line item and award type (RSU/PSU, Stock Options, ESPP) plus full share & fair value rollforwards; (7) Inventories by stage ($1,341.0M net at Q2 2026 across Raw Materials $334.4M, WIP $798.5M, Finished Goods $208.1M), PP&E by asset class, Geographic Long-Lived Assets (U.S., U.K., Other), Intangibles/IPR&D, and Operating & Finance Leases; (8) Monthly & Quarterly Share Repurchases from Item 2(c)/Item 5 (76 months through June 2026), Domestic vs. Foreign Pre-Tax Income, DTA/DTL breakdown, NOL/Tax Credit carryforwards, and Unrecognized Tax Benefits (UTB) rollforward; (9) Workforce by region (~6,600 total employees in FY25: 4,600 U.S. and 2,000 Ex-U.S.), DEF 14A CEO & NEO Pay Versus Performance and CEO Pay Ratio (80:1 in FY25; median employee $242,400), and Corporate Responsibility / ESG metrics (Scope 1, 2 & 3 GHG emissions, 73% renewable electricity, 82% green buildings, waste diversion, water, TRIR 0.13); (10) Audited UK Companies House statutory accounts (OCR) for Vertex Pharmaceuticals (Europe) Limited (02907620: $12,783.7M turnover, $999.9M net profit, $4,763.9M net assets in FY25) plus SEC XBRL for acquired subsidiaries Alpine Immune Sciences and Crinetics Pharmaceuticals; and (11) FRED Healthcare/Pharma Benchmarks and PostgreSQL DB Financial Statements.
  • No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I as restricted net assets of subsidiaries are below the 25% threshold), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted and OCR metrics; bound disclosures such as Q4 2025 JOURNAVX 'over 200 million covered lives' are excluded from table cells). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.

Không hiện vì thiếu các kỳ gần đây (11)

  • Commercial Launch, Patient Access, CF Disease Population & Wholesaler Concentration › JOURNAVX (suzetrigine, non-opioid NaV1.8 pain signal inhibitor) — Quarterly prescriptions filled (Rx) › JOURNAVX — Covered lives across commercial & government payers (millions)
  • Commercial Launch, Patient Access, CF Disease Population & Wholesaler Concentration › JOURNAVX (suzetrigine, non-opioid NaV1.8 pain signal inhibitor) — Quarterly prescriptions filled (Rx) › JOURNAVX — Covered lives with unrestricted access (no prior auth / step edit) (millions)
  • Commercial Launch, Patient Access, CF Disease Population & Wholesaler Concentration › CASGEVY (exagamglogene autotemcel, CRISPR/Cas9 gene-edited therapy) — Patient infusions in period (patients) › CASGEVY — Cumulative patients infused since launch (patients)
  • Commercial Launch, Patient Access, CF Disease Population & Wholesaler Concentration › ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) — Countries with regulatory approval / reimbursement access (countries)
  • Net Product & Collaborative Revenues by Brand / Therapy & Geography › Total consolidated revenues ($M) › Net product revenues — Total ($M) › Cystic Fibrosis (CF) portfolio — Total CF net product revenues ($M)
  • Net Product & Collaborative Revenues by Brand / Therapy & Geography › Total consolidated revenues ($M) › Net product revenues — Total ($M) › Other CF products (SYMDEKO/SYMKEVI, ORKAMBI & KALYDECO combined, FY2024, $M)
  • Net Product & Collaborative Revenues by Brand / Therapy & Geography › Total consolidated revenues ($M) › Other revenues (collaborative & royalty revenues, $M) › Collaborative revenues (standalone historical, $M)
  • Granular R&D Breakdown (Research vs. Development), Segment Expenses & CRISPR Collaboration › Total Research and Development (R&D) expenses ($M) › Development expenses (clinical trials, regulatory & CMC) — Total ($M) › Development — Collaborative & milestone payments (FY2017–FY2021, $M)
  • Granular R&D Breakdown (Research vs. Development), Segment Expenses & CRISPR Collaboration › CRISPR Therapeutics Collaboration (CASGEVY JDCA, 60% VRTX / 40% CRISPR) — Net R&D expense ($M) › CRISPR Collaboration — AIPR&D upfront & milestone expense ($M)
  • Share Repurchases (Monthly & Quarterly) & Income Taxes / UTB Rollforward › Net deferred tax assets (after valuation allowance & deferred tax liabilities, $M) › Net operating loss (NOL) carryforwards — U.S. federal ($M) › Tax credit carryforwards — U.S. federal ($M)
  • Subsidiary Statutory Filings (UK Companies House OCR) & Acquired Biotech Subsidiaries (Alpine & Crinetics) › Crinetics Pharmaceuticals, Inc. (CIK 0001699813, July 2026 acquisition agreement for PALSONIFY, ~$8.8B) — R&D expense ($M) › Crinetics Pharmaceuticals — Selling, general and administrative expense ($M)

Dữ liệu cập nhật 2026-11-02.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Non-GAAP Financial Performance & Reconciliations (Form 8-K Earnings Releases)

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Vertex Pharmaceuticals

See a number that looks wrong?